Fate Therapeutics falls as a trial of its B-cell lymphoma treatment produces mixed results.

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Here's what you need to know now for Monday, Jan. 22.

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

More Immunotherapy Buyouts Likely After Kite Sale

Fate's first subject has been treated with FATE-NK100 for AML and two additional clinical trials of FATE-NK100 for the treatment of multiple advanced solid tumor types will soon open.

These stocks look ready to break out and trade higher from current levels.

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Raymond James analyst Reni Benjamin says positive news may be ahead for these companies.

People who are traveling by air are about to see a change in recent trends.

Beverage giant is rolling out a new taste in its efforts to attract and keep a key demographic.

You can find savings on everything from EVs to solar panels in the Inflation Reduction Act.